CLINICAL_TRIALS trial_result · 2021-04-12

Clinical Trial Update: Safety and Efficacy of MP-214 in Patients With Schizophrenia [Phase 2, Phase 3]

A Phase 2/3 clinical trial evaluating MP-214 for schizophrenia has completed and its results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Tanabe Pharma Corporation | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-04-12